This is in contrast to previous published results of combining MAPK and PI3K/mTOR pathway inhibitors using a MEK and an Akt inhibitor in pancreatic cancer cells [67], which again confirms that the results of pathway perturbations highly rely on the inhibitors and the genetic background of the treated cells. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.